This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Drug management

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

There is evidence that drug treatment, in addition to having beneficial effects on the features of hyperkinetic disorder (HKD) and Attention Deficit/ Hyperactivity Disorder (ADHD), has positive effects on academic activity, productivity and relationships with family and peers.

All medication for ADHD should only be initiated by a healthcare professional with training and expertise in diagnosing and managing ADHD.

Healthcare professionals initiating medication for ADHD should:

  • be familiar with the pharmacokinetic profiles of all the short- and long-acting preparations available for ADHD
  • ensure that treatment is tailored effectively to the individual needs of the child, young person or adult
  • take account of variations in bioavailability or pharmacokinetic profiles of different preparations to avoid reduced effect or excessive adverse effects

Baseline assessment

  • NICE state that before starting medication for ADHD, people with ADHD should have a full assessment, which should include:
    • a review to confirm they continue to meet the criteria for ADHD and need treatment
    • a review of mental health and social circumstances, including:
      • presence of coexisting mental health and neurodevelopmental conditions
      • current educational or employment circumstances
      • risk assessment for substance misuse and drug diversion
      • care needs
    • a review of physical health, including:
      • a medical history, taking into account conditions that may be contraindications for specific medicines
      • current medication height and weight (measured and recorded against the normal range for age, height and sex)
      • baseline pulse and blood pressure (measured with an appropriately sized cuff and compared with the normal range for age)
      • a cardiovascular assessment an electrocardiogram (ECG)
        • is not needed before starting stimulants, atomoxetine or guanfacine, unless the person has any of the features in criteria for referral for specialist opinion (below), or a co-existing condition that is being treated with a medicine that may pose an increased cardiac risk (1)
      • if the treatment may affect the QT interval

    • referral for specialist opinion before commencing medication:
      • cardiology opinion before starting medication for ADHD if any of the following apply:
        • history of congenital heart disease or previous cardiac surgery
        • history of sudden death in a first-degree relative under 40 years suggesting a cardiac disease
        • shortness of breath on exertion compared with peers
        • fainting on exertion or in response to fright or noise
        • palpitations that are rapid, regular and start and stop suddenly (fleeting occasional bumps are usually ectopic and do not need investigation)
        • chest pain suggesting cardiac origin
        • signs of heart failure a murmur heard on cardiac examination
        • blood pressure that is classified as hypertensive for adults
      • paediatric hypertension specialist before starting medication for ADHD if blood pressure is consistently above the 95th centile for age and height for children and young people

Drug treatment choice - children aged 5 years and over and young people

  • methylphenidate (either short or long acting) as the first line pharmacological treatment
  • switching to lisdexamfetamine should be considered if a 6-week trial of methylphenidate at an adequate dose and not derived enough benefit in terms of reduced ADHD symptoms and associated impairment
  • dexamfetamine should be considered if ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile
  • atomoxetine or guanfacine should be offered if:
    • they cannot tolerate methylphenidate or lisdexamfetamine or
    • their symptoms have not responded to separate 6-week trials of lisdexamfetamine and methylphenidate, having considered alternative preparations and adequate doses

Drug treatment choice - adults

  • lisdexamfetamine or methylphenidate are options as first-line pharmacological treatment for adults with ADHD
    • switching to lisdexamfetamine should be considered for adults who have had a 6-week trial of methylphenidate at an adequate dose but have not derived enough benefit in terms of reduced ADHD symptoms and associated impairment
    • switching to methylphenidate should be considered for adults who have had a 6-week trial of lisdexamfetamine at an adequate dose but have not derived enough benefit in terms of reduced ADHD symptoms and associated impairment
    • dexamfetamine should be considered for adults whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile
  • atomoxetine should be offered to adults if:
    • they cannot tolerate lisdexamfetamine or methylphenidate or
    • their symptoms have not responded to separate 6-week trials of lisdexamfetamine and methylphenidate, having considered alternative preparations and adequate doses

For details then consult the full guideline (1).

Monitoring is detailed in the full guideline (1).

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.